Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche announces pharmaceutical product divestment

Roche announces pharmaceutical product divestment

13th August 2007

Roche has announced the divestment of three pharmaceutical products to Actavis – Bezalip, Rapilysin and Neotigason – with the firm reporting that these sales reflect the company’s decision to focus its efforts on key therapy areas.

The financial terms of this transaction have not been made public, while the combined sales of all three products last year reached 140 million Swiss francs (57.9 million pounds).

Subject to usual closing conditions, the transactions relating to these three drugs are forecast to close in a number of stages towards the end of the year and during the start of 2008.

Roche will continue its distribution of the three products in Latin America through a licensing deal with Actavis.

Bezalip and Rapilysin are both used to treat cardiovascular conditions, while Neotigason is used in dermatology.

“These transactions further underline Roche’s strategy of focussing on core products from its innovation-driven pharmaceutical and diagnostic divisions,” the company reported.

It added that focussing efforts on these two segments could potentially create much value, both financially for the firm and medically for patients.

In June 2007, Roche announced the $272.5 million (134.85 million pound) acquisition of DNA microarrays, consumables instruments and services firm NimbleGen to boost its position in the genomics research market.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.